Georgia N Valsami

List of Publications by Year
in descending order

80 papers	1,746 citations	257101 24 h-index	315357 38 g-index
80 all docs	80 docs citations	80 times ranked	2204 citing authors

#	Article	IF	Citations
1	Proâ€inflammatory cytokines/chemokines, TNFâ€Î±, ILâ€6 and MCPâ€1, as biomarkers for the nephroâ€and pneumoprotective effect of silibinin after hepatic ischemia/reperfusion: Confirmation by immunohistochemistry and qRTâ€PCR. Basic and Clinical Pharmacology and Toxicology, 2022, 130, 457-467.	1.2	5
2	Development of a Population Pharmacokinetic Model of Busulfan in Children and Evaluation of Different Sampling Schedules for Precision Dosing. Pharmaceutics, 2022, 14, 647.	2.0	4
3	Losartan Interactions with 2-Hydroxypropyl-Î²-CD. Molecules, 2022, 27, 2421.	1.7	4
4	A Comprehensive Review of the Cardiovascular Protective Properties of Silibinin/Silymarin: A New Kid on the Block. Pharmaceuticals, 2022, 15, 538.	1.7	9
5	Exercise training inhibits atherosclerosis progression and reduces VE-cadherin levels within atherosclerotic plaques in hypercholesterolemic mice. Biochemical and Biophysical Research Communications, 2022, , .	1.0	0
6	Charting the structural and thermodynamic determinants in phenolic acid natural product â€“ cyclodextrin encapsulations. Journal of Biomolecular Structure and Dynamics, 2021, 39, 2642-2658.	2.0	9
7	Population pharmacokinetics of anidulafungin in ICU patients assessing interâ€and intrasubject variability. British Journal of Clinical Pharmacology, 2021, 87, 1024-1032.	1.1	7
8	Omentin-1 and vaspin serum levels in patients with pre-clinical carotid atherosclerosis and the effect of statin therapy on them. Cytokine, 2021, 138, 155364.	1.4	7
9	The hepatoprotective effect of silibinin after hepatic ischemia/reperfusion in a rat model is confirmed by immunohistochemistry and qRT-PCR. Journal of Pharmacy and Pharmacology, 2021, 73, 1274-1284.	1.2	4
10	Flurbiprofen sodium microparticles and soft pellets for nose-to-brain delivery: Serum and brain levels in rats after nasal insufflation. International Journal of Pharmaceutics, 2021, 605, 120827.	2.6	9
11	Dose individualization of intravenous busulfan in pediatric patients undergoing bone marrow transplantation: impact and in vitro evaluation of infusion lag-time. Journal of Pharmacy and Pharmacology, 2021, 73, 1340-1350.	1.2	2
12	The cardiovascularâ€protective properties of saffron and its potential pharmaceutical applications: A critical appraisal of the literature. Phytotherapy Research, 2021, 35, 6735-6753.	2.8	12
13	Nasal powders of quercetin-Î²-cyclodextrin derivatives complexes with mannitol/lecithin microparticles for Nose-to-Brain delivery: In vitro and ex vivo evaluation. International Journal of Pharmaceutics, 2021, 607, 121016.	2.6	27
14	Nonalcoholic fatty liver disease: The role of quercetin and its therapeutic implications. Saudi Journal of Gastroenterology, 2021, 27, 319-330.	0.5	10
15	Effect of silibinin on the expression of MMP2, MMP3, MMP9 and TIMP2 in kidney and lung after hepatic ischemia/reperfusion injury in an experimental rat model. Acta Cirurgica Brasileira, 2021, 36, e360904.	0.3	1
16	Application of Neutralization and Technique for the Preparation of the BeneficialÂin Drug 2-Hydroxypropyl-Î²-Cyclodextrin with. Methods in Molecular Biology, 2021, 2207, 1-11.	0.4	2
17	Silibinin-hydroxypropyl-Î²-cyclodextrin (SLB-HP-Î²-CD) complex prevents apoptosis in liver and kidney after hepatic ischemia-reperfusion injury. Food and Chemical Toxicology, 2020, 145, 111731.	1.8	15
18	Preparation and Biophysical Characterization of Quercetin Inclusion Complexes with Î²-Cyclodextrin Derivatives to be Formulated as Possible Nose-to-Brain Quercetin Delivery Systems. Molecular Pharmaceutics, 2020, 17, 4241-4255.	2.3	35

#	Article	IF	Citations
19	Comparative pharmacokinetics of the three echinocandins in ICU patients. Journal of Antimicrobial Chemotherapy, 2020, 75, 2969-2976.	1.3	7
20	Antihypertensive activity and molecular interactions of irbesartan in complex with 2â€hydroxypropylâ€Î²â€cyclodextrin. Chemical Biology and Drug Design, 2020, 96, 668-683.	1.5	6
21	Population pharmacokinetics of micafungin over repeated doses in critically ill patients: a need for a loading dose?. Journal of Pharmacy and Pharmacology, 2020, 72, 1750-1760.	1.2	4
22	Use of natural anti-oxidants in experimental animal models of hepatic ischemia-reperfusion injury. Annals of Medicine and Surgery, 2020, 60, 592-599.	0.5	4
23	Hyperhydration using different hydration agents does not affect the haematological markers of the athlete biological passport in euhydrated volunteers. Journal of Sports Sciences, 2020, 38, 1924-1932.	1.0	3
24	Glycoprotein non-metastatic melanoma B expression after hepatic ischemia reperfusion and the effect of silibinin. Translational Gastroenterology and Hepatology, 2020, 5, 7-7.	1.5	5
25	Anti-inflammatory flurbiprofen nasal powders for nose-to-brain delivery in Alzheimerâ€™s disease. Journal of Drug Targeting, 2019, 27, 984-994.	2.1	21
26	Hostâ€“Guest Interactions between Candesartan and Its Prodrug Candesartan Cilexetil in Complex with 2-Hydroxypropyl-Î²-cyclodextrin: On the Biological Potency for Angiotensin II Antagonism. Molecular Pharmaceutics, 2019, 16, 1255-1271.	2.3	17
27	Effect of hyperhydration on the pharmacokinetics and detection of orally administered budesonide in doping control analysis. Scandinavian Journal of Medicine and Science in Sports, 2019, 29, 1489-1500.	1.3	6
28	Statinsâ€™ Withdrawal Induces Atherosclerotic Plaque Destabilization in Animal Modelâ€”A â€œReboundâ€• Stimulation of Inflammation. Journal of Cardiovascular Pharmacology and Therapeutics, 2019, 24, 377-386.	1.0	11
29	Hyperhydration Effect on Pharmacokinetic Parameters and Detection Sensitivity of Recombinant Human Erythropoietin in Urine and Serum Doping Control Analysis of Males. Journal of Pharmaceutical Sciences, 2019, 108, 2162-2172.	1.6	7
30	Preparation, chemical characterization and determination of crocetin's pharmacokinetics after oral and intravenous administration of saffron (Crocus sativus L.) aqueous extract to C57/BL6J mice. Journal of Pharmacy and Pharmacology, 2019, 71, 753-764.	1.2	19
31	Hyperhydration-Induced Decrease in Urinary Luteinizing Hormone Concentrations of Male Athletes in Doping Control Analysis. International Journal of Sport Nutrition and Exercise Metabolism, 2019, 29, 388-396.	1.0	4
32	Silibinin Improves TNF-Î± and M30 Expression and Histological Parameters in Rat Kidneys After Hepatic Ischemia/Reperfusion. Journal of Investigative Surgery, 2018, 31, 201-209.	0.6	15
33	Crocus sativus L. aqueous extract reduces atherogenesis, increases atherosclerotic plaque stability and improves glucose control in diabetic atherosclerotic animals. Atherosclerosis, 2018, 268, 207-214.	0.4	31
34	Silibinin Effect on Fas/FasL, HMGB1, and CD45 Expressions in a Rat Model Subjected to Liver Ischemia-Reperfusion Injury. Journal of Investigative Surgery, 2018, 31, 491-502.	0.6	24
35	The effect of athletes` hyperhydration on the urinary â€˜steroid profileâ€™ markers in doping control analysis. Drug Testing and Analysis, 2018, 10, 1458-1468.	1.6	8
36	Exploring the oxidation and iron binding profile of a cyclodextrin encapsulated quercetin complex unveiled a controlled complex dissociation through a chemical stimulus. Biochimica Et Biophysica Acta - General Subjects, 2018, 1862, 1913-1924.	1.1	28

#	Article	IF	Citations
37	Exploring the interactions of irbesartan and irbesartanâ€“2-hydroxypropyl-Î²-cyclodextrin complex with model membranes. Biochimica Et Biophysica Acta - Biomembranes, 2017, 1859, 1089-1098.	1.4	26
38	Saffron (Crocus sativus) intake provides nutritional preconditioning against myocardial ischemiaâ€“reperfusion injury in Wild Type and ApoE (â^'/â^') mice: Involvement of Nrf2 activation. Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, 919-929.	1.1	29
39	The impact of maternal- and neonatal-associated factors on human milk's macronutrients and energy. Journal of Maternal-Fetal and Neonatal Medicine, 2017, 30, 1302-1308.	0.7	62
40	Mapping the interactions and bioactivity of quercetinâ¿¿(2-hydroxypropyl)-Î²-cyclodextrin complex. International Journal of Pharmaceutics, 2016, 511, 303-311.	2.6	48
41	Drug Utilization Patterns and Costs of Erythropoiesis-Stimulating Agents in an Outpatient Setting in Greece. The Consultant Pharmacist, 2016, 31, 271-281.	0.4	1
42	Mother's breast milk supplemented with donor milk reduces hospital and health service usage costs in low-birthweight infants. Midwifery, 2016, 40, 109-113.	1.0	17
43	Bioassay for Determining Voriconazole Serum Levels in Patients Receiving Combination Therapy with Echinocandins. Antimicrobial Agents and Chemotherapy, 2016, 60, 632-636.	1.4	13
44	Improved outcomes of feeding low birth weight infants with predominantly raw human milk versus donor banked milk and formula. Journal of Maternal-Fetal and Neonatal Medicine, 2016, 29, 1131-1138.	0.7	30
45	Saffron: a natural product with potential pharmaceutical applications. Journal of Pharmacy and Pharmacology, 2015, 67, 1634-1649.	1.2	154
46	Investigation of the Interactions of Silibinin with 2-Hydroxypropyl-Î²-cyclodextrin through Biophysical Techniques and Computational Methods. Molecular Pharmaceutics, 2015, 12, 954-965.	2.3	55
47	Serum and tissue pharmacokinetics of silibinin after per os and i.v. administration to mice as a HP-Î²-CD lyophilized product. International Journal of Pharmaceutics, 2015, 493, 366-373.	2.6	36
48	Gas chromatographicâ€“mass spectrometric quantitation of busulfan in human plasma for therapeutic drug monitoring: A new on-line derivatization procedure for the conversion of busulfan to 1,4-diiodobutane. Journal of Pharmaceutical and Biomedical Analysis, 2014, 90, 207-214.	1.4	14
49	Keeping a Critical Eye on the Science and the Regulation of Oral Drug Absorption: A Review. Journal of Pharmaceutical Sciences, 2013, 102, 3018-3036.	1.6	28
50	Pharmacokinetics of doripenem in CSF of patients with non-inflamed meninges. Journal of Antimicrobial Chemotherapy, 2012, 67, 1722-1729.	1.3	11
51	Elucidating the Role of Dose in the Biopharmaceutics Classification of Drugs: The Concepts of Critical Dose, Effective In Vivo Solubility, and Dose-Dependent BCS. Pharmaceutical Research, 2012, 29, 3188-3198.	1.7	22
52	Supersaturated dissolution data and their interpretation: the TPGSâ€“carbamazepine model case. Journal of Pharmacy and Pharmacology, 2011, 63, 352-361.	1.2	18
53	Robust and Sensitive High-Performance Liquid Chromatographic-UV Detection Technique for the Determination of Tigecycline in Rabbit Plasma. Journal of AOAC INTERNATIONAL, 2011, 94, 847-856.	0.7	8
54	Use of 1-Anilino-8-napthalenesulphonate as an Ion Probe for the Potentiometric Study of the Binding of Sulphonamides to Bovine Serum Albumin and Plasma. Journal of Pharmacy and Pharmacology, 2011, 45, 434-438.	1.2	7

#	Article	IF	Citations
55	Computationalâ€Regulatory Developments in the Prediction of Oral Drug Absorption. Molecular Informatics, 2011, 30, 112-121.	1.4	1
56	Penetration of Intact Blood-Brain Barrier by Doripenem. Antimicrobial Agents and Chemotherapy, 2011, 55, 3637-3638.	1.4	5
57	In-vitro study on the competitive binding of diflunisal and uraemic toxins to serum albumin and human plasma using a potentiometric ion-probe technique. Journal of Pharmacy and Pharmacology, 2010, 58, 1467-1474.	1.2	13
58	Plasma profiles of lycopene after single oral and intravenous administrations in dogs. Journal of Pharmacy and Pharmacology, 2010, 58, 1211-1217.	1.2	10
59	Biopharmaceutical Classification Based on Solubility and Dissolution: A Reappraisal of Criteria for Hypothesis Models in the Light of the Experimental Observations. Basic and Clinical Pharmacology and Toxicology, 2010, 106, 168-172.	1.2	9
60	Effect of Cyclodextrin Complexation on the Aqueous Solubility and Solubility/Dose Ratio of Praziquantel. AAPS PharmSciTech, 2009, 10, 1444-51.	1.5	26
61	Development of a reaction-limited model of dissolution: Application to official dissolution tests experiments. International Journal of Pharmaceutics, 2008, 355, 114-125.	2.6	44
62	Biopharmaceutics classification systems for new molecular entities (BCS-NMEs) and marketed drugs (BCS-MD): Theoretical basis and practical examples. International Journal of Pharmaceutics, 2008, 361, 70-77.	2.6	22
63	Effect of pH and water-soluble polymers on the aqueous solubility of nimesulide in the absence and presence of <I>Î²</I>-cyclodextrin derivatives. Journal of Pharmacy and Pharmacology, 2008, 60, 1433-1439.	1.2	8
64	Modelling and simulation in drug absorption processes. Xenobiotica, 2007, 37, 1052-1065.	0.5	19
65	Solubilization and quantification of lycopene in aqueous media in the form of cyclodextrin binary systems. International Journal of Pharmaceutics, 2006, 309, 115-122.	2.6	40
66	Identification of Biowaivers Among Class II Drugs: Theoretical Justification and Practical Examples. Pharmaceutical Research, 2004, 21, 1567-1572.	1.7	68
67	Quantitative Biopharmaceutics Classification System: The Central Role of Dose/Solubility Ratio. Pharmaceutical Research, 2003, 20, 1917-1925.	1.7	143
68	The power law can describe the â€˜entireâ€™ drug release curve from HPMC-based matrix tablets: a hypothesis. International Journal of Pharmaceutics, 2003, 255, 199-207.	2.6	84
69	Non-linear regression analysis with errors in both variables: estimation of co-operative binding parameters. Biopharmaceutics and Drug Disposition, 2000, 21, 7-14.	1.1	8
70	Modeling of supersaturated dissolution data. International Journal of Pharmaceutics, 1999, 181, 153-157.	2.6	20
71	Studies on the interaction of diflunisal ion with cyclodextrins using ion-selective electrode potentiometry. European Journal of Pharmaceutical Sciences, 1999, 7, 271-278.	1.9	28
72	A displacement approach for competitive drugâ€“protein binding studies using the potentiometric 1-anilino-8-naphthalene-sulfonate probe technique. European Journal of Pharmaceutical Sciences, 1999, 9, 123-130.	1.9	24

#	Article	IF	Citations
73	Determination of fractal reaction dimension in dissolution studies. European Journal of Pharmaceutical Sciences, 1995, 3, 163-169.	1.9	28
74	General Treatment of Competitive Binding as Applied to the Potentiometric Ion Probe Technique: Application to the Interaction of Nonsteroidal Anti- Inflammatory Drugs with Bovine Serum Albumin. Journal of Pharmaceutical Sciences, 1994, 83, 1150-1154.	1.6	9
75	Automated flow-injection technique for use in dissolution studies of sustained-release formulations: Application to iron(II) formulations. Journal of Pharmaceutical and Biomedical Analysis, 1994, 12, 635-641.	1.4	15
76	Determination of association constants in cyclodextrin/drug complexation using the Scatchard plot: application to beta-cyclodextrin-anilinonaphthalenesulfonates. Pharmaceutical Research, 1992, 09, 1568-1574.	1.7	45
77	Complexation studies of cyclodextrins with tricyclic antidepressants using ion-selective electrodes. Pharmaceutical Research, 1992, 09, 94-100.	1.7	35
78	Binding study of the fluorescence probe 1-anilino-8-naphthalensulfonate to human plasma and human and bovine serum albumin using potentiometric titration. Pharmaceutical Research, 1991, 08, 888-892.	1.7	25
79	Binding Studies of Ions with Cyclodextrins Using Ion-Selective Electrodes. Journal of Pharmaceutical Sciences, 1990, 79, 1087-1094.	1.6	29
80	Construction of a naproxen ion-selective electrode and its application to pharmaceutical analysis. Analyst, The, 1989, 114, 387.	1.7	27